Date: 2012-11-08
Type of information: Grant
Company: Lophius Biosciences (Germany)
Investors: ZIM (Zentrales Innovationsprogramm Mittelstand)-solo-program (Germany)
Amount: 140K€
Funding type: grant
Planned used: This funding should help to broaden the scope of the T-Track® TB tests with respect to detection of latent tuberculosis (TB) and potential patient-monitoring of treated TB subjects.
Others: Lophius Biosciences has been awarded research funding of 140K€ under the scope of the ZIM-solo-program from the German government. The company has just reported about its first successfully concluded clinical Proof of Principle study with respect to detection of active tuberculosis (TB) using its novel T-Track® TB test which is based on Lophius Biosciences proprietary Reverse T Cell Technology (RT Technology).
This funding should help to broaden the scope of the T-Track® TB tests with respect to detection of latent TB and potential patient-monitoring of treated TB subjects.
Therapeutic area: Infectious diseases
